Alterity Therapeutics
ATHE
7 hedge funds and large institutions have $502K invested in Alterity Therapeutics in 2019 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 5 closing their positions.
36% less funds holding
Funds holding: 11 → 7 (-4)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
100% less capital inflows, than outflows
Capital inflows: $681 | Capital outflows: $141K
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$681 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$56.9K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$16K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$13.7K |
| 4 |
Claro Advisors
Boston,
Massachusetts
|
-$5K |
ATHE Hedge Fund Activity: Q1 2019 in Review
7 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Alterity Therapeutics (ATHE) for Q1 2019, worth a combined $502K — up 21% from $415K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of ATHE and 0 opened new positions — a net loss of 5 holders — while 2 trimmed existing stakes and 1 added.
The largest buyer was Morgan Stanley, adding an estimated $681. The largest seller was Susquehanna International Group, cutting an estimated $56.9K.
- 7 institutional investors held Alterity Therapeutics (ATHE) as of Q1 2019, down from 11 in Q4 2018.
- Funds reported $502K of Alterity Therapeutics stock for Q1 2019, up 21% quarter-over-quarter.
- 0 funds opened new Alterity Therapeutics positions in Q1 2019 and 5 closed out, a net change of -5 holders.
- The largest Alterity Therapeutics buyer in Q1 2019 was Morgan Stanley, an estimated $681 added.
- The largest Alterity Therapeutics seller in Q1 2019 was Susquehanna International Group, an estimated $56.9K sold.
Based on aggregated 13F filings for Q1 2019.